Sympathetic Nerve Activity in Renal Failure (SNS in CRF)

University of Erlangen-Nürnberg Medical School

Status and phase: Withdrawn; Phase 4

Conditions: Chronic Kidney Disease; Hypertension

Treatments: Drug: Rilmenidine; Drug: Nitrendipine

Study type: Interventional

Funder types: Other

Identifiers

NCT00892892

Re-No. 3186

Details and patient eligibility

About

The primary purpose is to assess the role of sympathetic activation for the development and progression of chronic renal failure. Using microneurography sympathetic activity will be registered in various stages of kidney affection or failure and hypertension.

A sympatholytic agent will be compared with a non-sympatholytic drug to asses the effect sympathetic activation and on the progression of kidney disease.

The effects of a sympatholytic agent on cardiovascular reactivity to various stressors wil be examined.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• chronic renal failure stages I-IV

Exclusion criteria

• pregnancy and lactation
• severe heart failure or ischemic heart disease
• patients with NYHA III-IV

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

0 participants in 2 patient groups

Arm 1

Experimental group

Description:

Rilmenidine as a sympatholytic agent for three months

Treatment:

Drug: Rilmenidine

Arm 2

Active Comparator group

Description:

Nitrendipine as a non-sympatholytic agent for three months

Treatment:

Drug: Nitrendipine